CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
High ImpactOriginal article

Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer

RegulatoryapprovedREVTORPYKPositive
AI Analysis

Summary

Celcuity's REVTORPYK has received FDA approval for the treatment of HR+/HER2- breast cancer, a significant regulatory milestone for the company.

Importance:9/10
Sentiment:
0.90
FDA approvaloncologybreast cancerHR+/HER2-
Related Companies

Read the original article

Published by yahoo_finance on July 14, 2026 9:19 PM

Read Original